Who are AGA2115's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Itovebi, Piqray, Placebo followed by Fisetin, Prodiax-23, TGR-1202, Copanlisib (BAY 80-6946).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aga2115.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AGA2115 — Competitive Intelligence Brief

AGA2115 (AGA2115) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PI3K inhibitor. Area: Oncology.

phase 2 PI3K inhibitor PI3K Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AGA2115 (AGA2115) — Angitia Incorporated Limited. AGA2115 is a small molecule drug that targets the PI3K/AKT/mTOR pathway.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AGA2115 TARGET	AGA2115	Angitia Incorporated Limited	phase 2	PI3K inhibitor	PI3K
Itovebi	inavolisib	Pfizer	marketed	Kinase Inhibitor [EPC]	phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)	2024-01-01
Piqray	alpelisib	Novartis	marketed		PI3Kα	2019-01-01
Placebo followed by Fisetin	Placebo followed by Fisetin	Wake Forest University Health Sciences	marketed	Senolytic agent	Multiple targets including PI3K/Akt and p38 MAPK pathways in senescent cells
Prodiax-23	Prodiax-23	SK Chemicals Co., Ltd.	phase 3	PI3K inhibitor	PI3K
TGR-1202	TGR-1202	Vanderbilt-Ingram Cancer Center	phase 3	PI3K delta inhibitor	PI3K delta
Copanlisib (BAY 80-6946)	Copanlisib (BAY 80-6946)	Bayer	phase 3	PI3K inhibitor	PI3K (phosphatidylinositol 3-kinase), pan-class I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PI3K inhibitor class)

Addpharma Inc. · 4 drugs in this class
AstraZeneca · 3 drugs in this class
Bayer · 3 drugs in this class
Ahn-Gook Pharmaceuticals Co.,Ltd · 2 drugs in this class
InventisBio Co., Ltd · 2 drugs in this class
Orient Pharma Co., Ltd. · 2 drugs in this class
Applied Biology, Inc. · 1 drug in this class
Angitia Incorporated Limited · 1 drug in this class
Aevi Genomic Medicine, LLC, a Cerecor company · 1 drug in this class
BPGbio · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AGA2115 — Competitive Intelligence Brief. https://druglandscape.com/ci/aga2115. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab